Biosynex SA (EPA:ALBIO)

Market Cap	19.69M -19.8%
Revenue (ttm)	115.13M -7.1%
Net Income	-58.22M
EPS	n/a
Shares Out	18.75M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	41,120
Open	1.135
Previous Close	1.060
Day's Range	1.040 - 1.135
52-Week Range	0.455 - 1.570
Beta	0.83
Analysts	n/a
Price Target	n/a
Earnings Date	May 14, 2026

About Biosynex

Biosynex SA designs, manufactures, and distributes rapid diagnostic tests to patients and healthcare professionals in France and internationally. The company develops and markets IVDs in the form of RDTs and TRODs, immunoblot, molecular biology, and POC for screening, diagnosis, and prevention. It also provides thermometers, tensiometers, oximetry, hearing protection products, oral and dental hygiene products, self-tests, thermal pads, inhalation chambers, and thermotherapy products, as well as anti-mosquito bracelets and waterproof, moisturizi...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2005
• Employees: 454
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALBIO

Financial Performance

In 2025, Biosynex's revenue was 115.13 million, an increase of 13.80% compared to the previous year's 101.17 million. Losses were -58.22 million, 34.4% more than in 2024.